Contemplating HPV vaccination in Japan during the time of COVID-19

DOI Web Site PubMed 被引用文献1件 オープンアクセス
  • Ai Miyoshi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Japan
  • Yutaka Ueda
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Japan
  • Tadashi Kimura
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Japan

この論文をさがす

説明

The Coronavirus Disease 2019 (COVID-19) pandemic has been growing, including in Japan where it has been estimated that as many as 3.1% of patients positive for new CoV strain SARS-CoV-2 might die of COVID-19-related respiratory failure. Meanwhile, human papillomavirus (HPV) is spreading in Japan. The fatality rate for HPV-associated cancers after infection with HPV is as much as that for COVID-19 in Japan, although the time to disease is much longer for HPV. Among advanced countries, the cervical cancer screening rate in Japanese females is very low. The Japanese Ministry of Health, Labor and Welfare (MHLW) suspended its official recommendation for HPV vaccination in June 2013 due to alleged adverse post-vaccination events in several young girls, such as chronic pain and motor impairment, which were repeatedly reported in the media. Subsequently, the rate for vaccinating girls plummeted from approximately 70% to the current rate of 1% or less. Women should accept HPV vaccination for the eventual prevention of cervical cancer with the same passion they are for COVID-19 testing.

収録刊行物

被引用文献 (1)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ